| Location within campus: | Laboratory 12 of the Biomedicine Unit (UBIMED) |
| Phone: | 5623-1333 Ext. 39808 |
| Head of Laboratory: | Dr. Federico Ávila Moreno Full Professor B f.avila@unam.mx |
| Researchers affiliated to the laboratory: | Dr. Irlanda Peralta Arrieta ip.arrieta@hotmail.com |
| Technicians affiliated to the laboratory: | Dr. Leonel Armas Lopez larmas@unam.mx |
| Research lines per researcher: | Our research group focuses on cellular, molecular, genetic, and epigenetic studies in infectious, immunological, and oncological lung diseases. |
Multidisciplinary study of degenerative, infectious, and oncological lung diseases, focusing on the identification of genetic, transcriptional, and epigenetic regulatory mechanisms of biomarkers involved in disease progression, prognosis, and therapy response. We employ strategies such as genome and epigenome-wide analysis for functional validation, both preclinical in animal models and clinical in patients.
An Epigenome Landscape For MEOX2 Transcription Factor: An
Occupancy Study By ChIP-Seq and Multi-Comparative Bioinformatic Analyses In Lung Cancer Cells. Armas López L, Priscila Pineda, Octavio Augusto Trejo, Peralta Arrieta I, Arrieta O, Zúñiga J, Ávila-Moreno Federico. Trends in Cancer, Impact Factor: 7.29. Submitted 2021.
Clinical and immunological factors that distinguish COVID-19 from pandemic influenza A(H1N1). José Alberto Choreño-Parra, Luis Armando Jiménez-Álvarez, Alfredo Cruz-Lagunas, Tatiana Sofía Rodríguez-Reyna, et al., Jorge Salas-Hernández, Patricio Santillán-Doherty, Justino Regalado, Angélica Hernández-Martínez, Lorena Orozco, Federico Ávila-Moreno, Ethel Awilda García-Latorre, Carmen M. Hernández-Cárdenas, Shabaana A. Khader, Albert Zlotnik, and Joaquín Zúñiga. Frontiers In Immunology, Accepted 2021. doi: 10.3389/fimmu.2021.593595. ISSN: 1664-3224. Impact Factor: 5.085.
Expression of Surfactant protein D (SP-D) distinguishes severe
pandemic influenza A(H1N1) from COVID-19. José Alberto Choreño-Parra, Luis Armando Jiménez-Álvarez, Gustavo Ramírez-Martínez, Alfredo Cruz-Lagunas, et al., Federico Ávila-Moreno, Guillermo Domínguez-Cherit, Tatiana Sofía Rodríguez-Reyna, Philip A. Mudd, Carmen Margarita Hernández-Cárdenas, Shabaana A. Khader, and Joaquín Zúñiga. The Journal of Infectious Diseases 2021. https://doi.org/10.1093/infdis/jiab113. ISSN: 1537-6613. Impact Factor: 5.022.
LncRNA SOX2-OT regulates AKT/ERK and SOX2/GLI-1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases. Herrera Solorio MA, Peralta Arrieta I, Armas López L, Hernández Cigala N, Mendoza Milla C, Ortiz Quintero B, Catalán Cardenas R, Pineda Villegas P, Rodríguez Villanueva E, Trejo Iriarte CG, Zúñiga J, Arrieta O, Ávila-Moreno Federico. Molecular Oncology 2020. https://doi.org/10.1002/1878-0261.12875., ISSN: 1878-0261. Impact Factor: 6.574.
CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Non-Small Cell Lung Cancer. Rodrigo Catalán, Mario Orozco-Morales, Norma Y. Hernández-Pedro, Alberto Guijosa, Ana L. Colín-González, Federico Ávila-Moreno and Oscar Arrieta.
Journal Of Immunology Res 2020: 9435030. doi: 10.1155/2020/9435030. eCollection 2020., ISSN: 2314-7156. Impact Factor: 3.247.
| Entry profile of potential thesis students: | Enthusiastic, responsible, and committed students interested in the multidisciplinary study at the molecular, pre-clinical, and clinical levels of lung diseases in humans. This involves using both cellular and animal models to establish clinical correlations in patients. |
| Service Social Data: | Epigenomics, Chronic Degenerative Diseases, and Lung Cancer. Program Code: 2021-12/63-1335 Students will engage in experimental and theoretical academic activities related to the study of degenerative lung diseases in humans. |